Spironolactone improves diastolic function in the elderly
- PMID: 16274097
- PMCID: PMC6653852
- DOI: 10.1002/clc.4960281008
Spironolactone improves diastolic function in the elderly
Abstract
Background: Diastolic dysfunction is common in the elderly. Increased myocardial fibrosis, a major determinant of diastolic function, has been observed with advancing age. Spironolactone prevents age-related increases in myocardial fibrosis in old normotensive rats.
Hypothesis: Spironolactone, via its antifibrotic activity, can improve diastolic function in the elderly with isolated diastolic dysfunction.
Methods: The study was a prospective, double-blind, randomized, placebo-controlled trial. Thirty elderly subjects between 60 and 85 years of age with isolated diastolic dysfunction and no contraindications for spironolactone were randomized to 25 mg/day of spironolactone or placebo for 4 months. Mitral E/A and deceleration time, plasma levels of carboxy-terminal of procollagen type I (PICP), and brain natriuretic peptide (BNP) were measured at baseline and at the end of 4 months. Plasma level of potassium was also monitored to prevent clinically significant hyperkalemia.
Results: There was no serious adverse event or clinically significant hyperkalemia in the spironolactone group. Compared with baseline values, spironolactone significantly improved mitral E/A ratio (0.71 +/- 0.08 vs. 0.84 +/- 0.19, p = 0.025) and deceleration time (285.5 +/- 73.1 vs. 230.0 +/- 54.7, p = 0.035). There were no significant differences in the magnitude of change in the levels of PICP and BNP between the two treatment groups.
Conclusion: Spironolactone may improve diastolic function in the elderly.
References
-
- Kannel WB, Belanger AJ: Epidemiology of heart failure: Am Heart J 1991; 121: 951–957 - PubMed
-
- Kannel WB: Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur Heart J 1987; 8 (suppl F): 23–26 - PubMed
-
- Kitzman DW: Diastolic function in the elderly, genesis and diagnostic and therapeutic implications. Cardiol Clin 2000; 18: 597–617 - PubMed
-
- Zannad F, Dousset B, Alla F: Treatment of congestive heart failure, interfering the aldosterone‐cardiac extracellular matrix relationship. Hypertension 2001; 38: 1227–1232 - PubMed
-
- Brilla C, Weber K: Reactive and reparative myocardial fibrosis in arterial hypertension in rats. Cardiovasc Res 1992; 26: 671–677 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources